AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26551263
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of velpatasvir once daily
Trial: 26551263
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of velpatasvir plus ribavirin
Trial: 21134456
Drug: Hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent vaccine formulations (PRP-T, 12μg; PRP-OMPC, 3μg or 6μg)
Trial: 21134456
Drug: Hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent vaccine formulations (PRP-OMPC, 3μg or 6μg)
Trial: 21134456
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.5mL intramuscular dose of diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b+hepatitis B vaccine)
Trial: 17174559
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) infusion at a dose of 0.1mg/kg/h during rewarming period of CPB
Trial: 9813513
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SNP infusion)
Trial: 27646937
Drug: Remifentanil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.1 μg/kg/min
Trial: 27646937
Drug: Remifentanil 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.2 μg/kg/min
Trial: 27646937
Drug: Remifentanil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.3 μg/kg/min
Trial: 27646937
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including all doses of remifentanil)
Trial: 27941730
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg/day) for 12 weeks
Trial: 17499360
Drug: Succimer chelation
RxNorm normalized name: Succimer
DrugBank: Succimer (DB00566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Succimer chelation therapy
Trial: 15479125
Drug: Lp(a) levels
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) levels in women with aCAD(+), median 442 units/l, p<0.001
Trial: 15479125
Drug: Lp(a) levels
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) levels in men with aCAD(+), median 274 units/l, p<0.001
Trial: 15479125
Drug: HDL cholesterol
RxNorm normalized name: HDL cholesterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL cholesterol levels in women with aCAD(+), 1.09 mmol/l, p<0.05
Trial: 15479125
Drug: Triglycerides in
RxNorm normalized name: omega-3-triglycerides incl. other esters and acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides in women with aCAD(+), 1.82 mmol/l, p<0.05
Trial: 15479125
Drug: Lp(a) levels
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) levels in men with aCAD(-), median 138 units/l
Trial: 15479125
Drug: Lp(a) levels
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) levels in women with aCAD(-), median 145 units/l
Trial: 11463010
Drug: Continued oral
RxNorm normalized name: Entex HC Discontinued Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued oral anticoagulant therapy for 9 additional months
Trial: 11463010
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of oral anticoagulant therapy after 3 months
Trial: 9750033
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (cisplatin + etoposide) plus radiotherapy followed by additional radiotherapy and 2 additional cycles of chemotherapy
Trial: 8032575
Drug: Euphylong (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphylong (once-daily evening administration)
Trial: 28300856
Drug: Halobetasol Propionate
RxNorm normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol Propionate Lotion, 0.05% (HBP Lotion)
Trial: 28300856
Drug: Halobetasol Propionate
RxNorm normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol Propionate Cream, 0.05% (HBP Cream)
Trial: 12492745
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg
Trial: 11899817
Drug: Intensive peloidobalneotherapy
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive peloidobalneotherapy (daily procedures with 4-5 hours interval)
Trial: 10421182
Drug: Calf-thigh sequential
RxNorm normalized name: thymus gland-calf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf-thigh sequential pneumatic compression
Trial: 2285255
Drug: IL-2 plus
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 plus MLT (10 mg/day orally at 8.00 p.m.)
Trial: 31122901
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus chemotherapy (carboplatin and nab-paclitaxel)
Trial: 25148955
Drug: FVOO (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVOO (30 mL, OOPC=961 mg/kg)
Trial: 25148955
Drug: VOO (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VOO (30 mL, OOPC=289 mg/kg)
Trial: 25148955
Drug: FVOO (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVOO (30 mL)
Trial: 23511366
Drug: Left lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left lateral position with 2 mL hyperbaric bupivacaine 0.5%
Trial: 23511366
Drug: Modified lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified lateral position with 2 mL hyperbaric bupivacaine 0.5%
Trial: 23511366
Drug: Sitting position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting position with 2 mL hyperbaric bupivacaine 0.5%
Trial: 19894328
Drug: Menatretenone 45
RxNorm normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatretenone 45 mg twice a day
Trial: 16735933
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation of hormone therapy (group 1)
Trial: 16735933
Drug: Gradual discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual discontinuation of hormone therapy (group 2)
Trial: 31064779
Drug: glasdegib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glasdegib + low-dose cytarabine (LDAC)
Trial: 23512892
Drug: Leptin administration
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin administration via subcutaneous injection twice daily for 16 weeks
Trial: 21811161
Drug: Standard-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose regimen (rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, all twice daily for 10 days)
Trial: 21811161
Drug: Half-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose regimen (rabeprazole 10 mg, amoxicillin 500 mg, clarithromycin 250 mg, all twice daily for 10 days)
Trial: 21811161
Drug: Standard-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose regimen
Trial: 21811161
Drug: Half-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose regimen
Trial: 10199760
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg)
Trial: 2856542
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose beclomethasone (200 micrograms bid)
Trial: 2856542
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose beclomethasone (1000 micrograms bid)
Trial: 30921005
Drug: Lycopene supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene supplements (15 mg capsules/day)
Trial: 30921005
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea supplements (600 mg/day epigallocatechin gallate)
Trial: 28851296
Drug: Procalcitonin antibiotic
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin antibiotic prescribing guideline
Trial: 28449281
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg varenicline
Trial: 17022368
Drug: Streblus asper
RxNorm normalized name: Asper-Flex
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Streblus asper leaf extract (SAE) solution (80 mg/ml)
Trial: 8987188
Drug: Avocado enriched
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avocado enriched diet (2000 Kcal, lipids 53% MFA 49 g saturated/unsaturated ratio 0.54)
Trial: 8987188
Drug: Isocaloric control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric control diet (MFA 34 g, saturated/unsaturated ratio 0.7)
Trial: 23306427
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 100 mg of rebamipide three times a day
Trial: 23306427
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 100 mg celecoxib twice daily
Trial: 21292168
Drug: Alvimopan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan 0.5 mg twice daily
Trial: 21292168
Drug: Alvimopan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan 0.5 mg once daily
Trial: 19719843
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol with rFSH and pre‐treatment with hCG (200 IU/day for 7 days)
Trial: 19719843
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol with rFSH and pre‐treatment with hCG
Trial: 15226339
Drug: Heparin every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin every 2 weeks for 12 months
Trial: 11520428
Drug: Garlic supplement
RxNorm normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplement
Trial: 23737323
Drug: Topical nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nifedipine ointment (5 min twice daily for 4 weeks)
Trial: 23737323
Drug: Topical nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nifedipine ointment
Trial: 23737323
Drug: Lateral internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral internal sphincterotomy (LIS) and Topical nifedipine ointment
Trial: 22078193
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 days followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses
Trial: 9442429
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of metronidazole 25% dental gel
Trial: 1545086
Drug: Clean Room
RxNorm normalized name: Pharma-Wipe Clean Room 12 x 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clean Room (CR) therapy
Trial: 22723578
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin (INS group)
Trial: 22723578
Drug: Triple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple oral therapy (TOT group)
Trial: 21171670
Drug: Lesogaberan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan (150 mg twice daily)
Trial: 21171670
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lesogaberan and esomeprazole
Trial: 1695070
Drug: Terfenadine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (300 mg twice daily)
Trial: 1695070
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg or 300 mg)
Trial: 686240
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of tinidazole twice daily for 7 days
Trial: 18471084
Drug: Magnitude, frequency,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnitude, frequency, or subclass of PfMSP5 or PvMSP5 IgG antibodies
Trial: 11171280
Drug: Methionine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine (0.1 mg/kg)
Trial: 31465720
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 g)
Trial: 23937319
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + EV (6 mg/day on day 10-14)
Trial: 23937319
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + placebo (vitamin B)
Trial: 23937319
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + EV
Trial: 15151838
Drug: V+D+M treatment
RxNorm normalized name: M-End Max D
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V+D+M treatment protocol
Trial: 1971165
Drug: Terfenadine (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (180 mg)
Trial: 2571320
Drug: Terfenadine (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (180 mg) plus Flurbiprofen (100 mg)
Trial: 9021434
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg)
Trial: 15288334
Drug: Delayed preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed preparation
Trial: 31032601
Drug: Successful percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful percutaneous treatment of CTO
Trial: 27914274
Drug: Vaginal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prostaglandin E2 gel (Prepidil®, dinoprostone) before labor (PGE group, n=90)
Trial: 27914274
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (unmedicated group, n=90)
Trial: 11186596
Drug: Combined walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined walking and conversation treatment
Trial: 6307178
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg daily for 3 consecutive days every 2 weeks)
Trial: 23499231
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CBT) with body image component using Virtual Reality techniques
Trial: 23499231
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CBT) without body image component
Trial: 16374671
Drug: Participants told
RxNorm normalized name: toldimfos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants told they may or may not be receiving a drug (conditional expectations)
Trial: 7908244
Drug: Ebastine 10
RxNorm normalized name: ebastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10 mg (5-10 years) or 20 mg (11-15 years) once daily before breakfast
Trial: 3530644
Drug: Five bronchodilator
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five bronchodilator drugs (specific drugs not mentioned)
Trial: 3530644
Drug: Metered-dose inhalers
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhalers delivery method
Trial: 27489153
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual with a booklet detailing locally available social activities.
Trial: 30789856
Drug: Ilaprazole 10
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10 mg
Trial: 25041486
Drug: Ilaprazole 20
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 20 mg
Trial: 25041486
Drug: Ilaprazole 40
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 40 mg
Trial: 18448989
Drug: Humerus segment
RxNorm normalized name: Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humerus segment with platelet gel
Trial: 8973987
Drug: 0.6 gm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 gm, 1.2 gm, and 1.8 gm doses of oxaprozin given on an empty stomach in a randomized, crossover trial (n = 35)
Trial: 8973987
Drug: 1.2 gm
RxNorm normalized name: Omtryg 1.2 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 gm once daily for 8 days (n = 12)
Trial: 8973987
Drug: 1.8 gm
RxNorm normalized name: Calcionate 1.8 GM per 5 ML Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 gm once daily for 8 days (n = 24)
Trial: 9818712
Drug: Multiple-dose administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose administration
Trial: 9818712
Drug: Single-dose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration
Trial: 8973987
Drug: Repetitive dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive dosing of oxaprozin
Trial: 30222367
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg/d)
Trial: 18834786
Drug: Oral coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral coenzyme Q10, 150 to 180 mg/d, for 7 to 10 days preoperatively
Trial: 16103233
Drug: Quartile of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartile of patients with the biggest average decrease in hemoglobin (from 14.2 to 12.6 g/dL)
Trial: 11967028
Drug: Somatostatin +
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin + low dose insulin (0.1 mU/kg/min)
Trial: 11967028
Drug: Somatostatin +
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin + high dose insulin (1.5 mU/kg/min)
Trial: 11967028
Drug: Insulin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (1.5 mU/kg/min) + somatostatin
Trial: 10589750
Drug: IT DepoCyt
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT DepoCyt (50 mg doses, up to six doses over 3 months)
Trial: 10589750
Drug: IT methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IT methotrexate (10 mg doses, up to sixteen doses over 3 months)
Trial: 1378139
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg carvedilol b.i.d.
Trial: 12393768
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate 30 mg kg(‐1)
Trial: 7763157
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 90 mL of saline and dextrose into the knee joint cavity
Trial: 30966728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no injection)
Trial: 2155569
Drug: 6‐month regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐month regimen (self‐administered isoniazid and rifampin daily for 24 weeks, plus pyrazinamide daily during the first 8 weeks)
Trial: 6455969
Drug: Biotin treatment
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biotin treatment
Trial: 6455969
Drug: Essential fatty
RxNorm normalized name: essential fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential fatty acid treatment